GlaxoSmithKline (GSK) Price & Analysis

Compare

903 Followers

GSK Stock Chart & Stats

Day’s Range― - ―

52-Week Range1,242.50p - 1,823.50p

Previous CloseN/A

Volume367.08K

Average Volume (3M)10.53M

Market Cap

£58.65B

Enterprise Value73.93B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)18.8

Beta0.72

Next Earnings

Jul 30, 2025

EPS Estimate

0.43

Next Dividend Ex-Date

May 15, 2025

Dividend Yield4.42%

Share Statistics

EPS (TTM)0.45

Shares Outstanding4,109,037,000

10 Day Avg. Volume8,773,930

30 Day Avg. Volume10,525,169

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£1,404.46

Price Target Upside2.97% Upside

Rating ConsensusHold

Number of Analyst Covering13

---

GlaxoSmithKline News

---

Bulls Say, Bears Say

Bulls Say

Product LaunchThe launch of Nucala for COPD has shown positive results in clinical trials, potentially providing an advantage over competing treatments.

Product PerformanceJemperli has a broad endometrial label and is the only PD1/L1 with significant overall survival in first-line treatment, offering opportunities for combination with other drugs.

Strategic ManagementGSK's strategic focus on navigating and mitigating tariffs is seen as a positive capability to manage external challenges.

Bears Say

Earnings GrowthGSK is projected to have the worst EPS growth rate in the sector between 2026 and 2029, with a decline of 5% as key franchises mature or decline.

Loss Of ExclusivityGSK's longer-term challenges with loss of exclusivity and growth issues lead to a reiterated underperform rating.

Research And DevelopmentHigher research and development expenses are expected to impact GSK's earnings per share negatively in the coming years.

---

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

1.10% Insiders

11.11%

Mutual Funds

0.08% Other Institutional Investors

75.90% Public Companies and

Individual Investors

Detailed Ownership Overview >

GSK FAQ

What was GlaxoSmithKline’s price range in the past 12 months?

GlaxoSmithKline lowest share price was 1242.50p and its highest was 1823.50p in the past 12 months.

What is GlaxoSmithKline’s market cap?

GlaxoSmithKline’s market cap is £58.65B.

When is GlaxoSmithKline’s upcoming earnings report date?

GlaxoSmithKline’s upcoming earnings report date is Jul 30, 2025 which is in 82 days.

How were GlaxoSmithKline’s earnings last quarter?

GlaxoSmithKline released its earnings results on Apr 30, 2025. The company reported 0.449p earnings per share for the quarter, beating the consensus estimate of 0.4p by 0.049p.

Is GlaxoSmithKline overvalued?

According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does GlaxoSmithKline pay dividends?

GlaxoSmithKline pays a Annually dividend of 15.999p which represents an annual dividend yield of 4.42%. See more information on GlaxoSmithKline dividends here

What is GlaxoSmithKline’s EPS estimate?

GlaxoSmithKline’s EPS estimate is 0.43.

How many shares outstanding does GlaxoSmithKline have?

GlaxoSmithKline has 4,109,037,000 shares outstanding.

What happened to GlaxoSmithKline’s price movement after its last earnings report?

GlaxoSmithKline reported an EPS of 0.449p in its last earnings report, beating expectations of 0.4p. Following the earnings report the stock price went up 3.596%.

Which hedge fund is a major shareholder of GlaxoSmithKline?

Currently, no hedge funds are holding shares in GB:GSK

---

GlaxoSmithKline Stock Smart Score

Underperform

Fundamentals

Return on Equity

22.52%

Trailing 12-Months

Asset Growth

3.75%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

GlaxoSmithKline

GlaxoSmithKline (GSK) is a global healthcare company that researches, develops, and manufactures a broad range of innovative products in three primary sectors: pharmaceuticals, vaccines, and consumer healthcare. The company is headquartered in Brentford, London, and operates worldwide, focusing on creating innovative solutions to improve the well-being of people around the world. GSK's core product offerings include prescription medicines, vaccines for the prevention of various diseases, and consumer healthcare products such as over-the-counter medicines, oral health, nutrition, and wellness products.

---

GSK Stock 12 Month Forecast

Average Price Target

1,404.46p

▲(2.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"12p","2291":"2,291p","581.75":"581.8p","1151.5":"1,151.5p","1721.25":"1,721.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.29K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1404.46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.40K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">13.55p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,581.75,1151.5,1721.25,2291],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1463,1526.6153846153845,1590.2307692307693,1653.8461538461538,1717.4615384615386,1781.076923076923,1844.6923076923076,1908.3076923076924,1971.923076923077,2035.5384615384614,2099.153846153846,2162.7692307692305,2226.3846153846152,{"y":2290,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1463,1458.4969230769232,1453.993846153846,1449.4907692307693,1444.9876923076922,1440.4846153846154,1435.9815384615385,1431.4784615384615,1426.9753846153847,1422.4723076923078,1417.9692307692308,1413.466153846154,1408.9630769230769,{"y":1404.46,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1463,1351.503846153846,1240.0076923076922,1128.5115384615385,1017.0153846153846,905.5192307692307,794.0230769230769,682.5269230769231,571.0307692307692,459.53461538461534,348.03846153846143,236.54230769230776,125.04615384615386,{"y":13.55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1638.13,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1711.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1478.38,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1478.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1614.15,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1488,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1388.24,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1326.57,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1331.51,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1389.36,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1466.5,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1469,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1463,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >